Discoid lupus erythematosus. Discoid lupus erythematosus
Conditions
Interventions
Intervention 1: Intervention group: taking oral vitamin D3 1000 tablets once a day for 3 months produced by Abidi factory. Intervention 2: Control group: taking placebo once a day for 3 months.
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Aged over 18 years Patients with DLE whose initial diagnosis based on clinical manifestations was confirmed during a histopathological study of a skin sample sent to the pathology department Referred to the dermatology clinic of Sina Hospital in Tabriz Providing Informed consent
Exclusion criteria
Exclusion criteria: Systemic lupus erythematosus Active kidney disease Hepatitis Malabsorption syndrome Corticosteroid, dietary supplements and contraceptives, or anticonvulsants (phenytoin and phenobarbital) users People with liver enzymes over 40 Abnormal sensitivity to vitamin D Pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The severity of discoid lupus erythematosus using CLAS criteria. Timepoint: Measurements before starting treatment and after 3 months of oral vitamin D treatment. Method of measurement: Cutaneous LE Disease Area and Severity Index (CLAS) criteria. | — |
Secondary
| Measure | Time frame |
|---|---|
| Vitamin D levels. Timepoint: Before and after the treatment period 3 months. Method of measurement: Individuals will undergo venous blood draw from the Antecubital area after 14-14 hours of fasting. The obtained samples will be measured by vitamin D level by quantitative luminescence method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBahareh Mehramuz
Tabriz University of Medical Sciences
Outcome results
None listed